{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:53:32Z","timestamp":1777114412021,"version":"3.51.4"},"reference-count":28,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","award":["UMF0011528"],"award-info":[{"award-number":["UMF0011528"]}],"id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","award":["212588"],"award-info":[{"award-number":["212588"]}],"id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK130378"],"award-info":[{"award-number":["R01DK130378"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Nonsurgical medical treatments are often performed for Cushing\u2019s disease due to high recurrence rates. However, current medical treatment that targets corticotroph adenomas are limited. To develop a treatment that specifically targets corticotrophs in Cushing\u2019s disease, it is necessary to identify corticotroph lineage\u2013specific proteins, which are involved in the Cushing\u2019s tumor phenotype. We have previously reported that the expression of E2F transcription factor 1 (E2F1), one of the cell cycle regulatory proteins, was increased in corticotrophs in Cushing\u2019s disease model mice and was involved in the regulation of POMC gene expression. Phosphorylation of Ser337 of E2F1 (pS337-E2F1) facilitates its binding to the POMC promoter, which was suggested to contribute to elevated POMC expression in corticotrophs. Here, we report that E2F1 expression is specific to the corticotroph lineage in normal human pituitaries and that the E2F1 protein is localized in the cytosol in normal corticotrophs. We show that pS337-E2F1 is localized in the nucleus specifically in Cushing\u2019s tumors, while it is localized in the perinuclear cytoplasm in the normal pituitary. This observation demonstrates that pS337 is a marker for Cushing\u2019s tumors and suggests that phosphorylation of E2F1 may be a target for developing a novel pharmacological treatment for tumorigenesis and hormone dysregulation of Cushing\u2019s disease.<\/jats:p>","DOI":"10.1210\/endocr\/bqac086","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T11:42:31Z","timestamp":1654774951000},"source":"Crossref","is-referenced-by-count":9,"title":["Aberrant Nuclear Translocation of E2F1 and Its Association in Cushing\u2019s Disease"],"prefix":"10.1210","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4451-1668","authenticated-orcid":false,"given":"Takako","family":"Araki","sequence":"first","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, University of Minnesota , Minneapolis, MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Genetics, Cell Biology and Development, University of Minnesota , MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Department of Genetics, Cell Biology and Development, University of Minnesota , MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0043-9705","authenticated-orcid":false,"given":"Yasuhiko","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Genetics, Cell Biology and Development, University of Minnesota , MN , USA"},{"name":"Stem Cell Institute, University of Minnesota , Minneapolis, MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"issue":"9","key":"2022063018185683600_CIT0001","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"2022063018185683600_CIT0002","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022063018185683600_CIT0003","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/EJE-07-0514","article-title":"Ketoconazole revisited: a preoperative or postoperative treatment in Cushing\u2019s disease","volume":"158","author":"Castinetti","year":"2008","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2022063018185683600_CIT0004","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1530\/EJE-16-0662","article-title":"Cabergoline for Cushing\u2019s disease: a large retrospective multicenter study","volume":"176","author":"Ferriere","year":"2017","journal-title":"Eur J Endocrinol."},{"issue":"10","key":"2022063018185683600_CIT0005","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med."},{"issue":"3","key":"2022063018185683600_CIT0006","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022063018185683600_CIT0007","doi-asserted-by":"crossref","first-page":"D11","DOI":"10.1530\/EJE-21-0344","article-title":"Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma","volume":"185","author":"Greenman","year":"2021","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2022063018185683600_CIT0008","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/jcem.83.2.4556","article-title":"Cabergoline in the treatment of acromegaly: a study in 64 patients","volume":"83","author":"Abs","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2022063018185683600_CIT0009","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1172\/JCI60417","article-title":"EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas","volume":"121","author":"Fukuoka","year":"2011","journal-title":"J Clin Invest."},{"issue":"2","key":"2022063018185683600_CIT0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1210\/js.2016-1053","article-title":"EGFR induces E2F1-mediated corticotroph tumorigenesis","volume":"1","author":"Araki","year":"2017","journal-title":"J Endocr Soc."},{"issue":"11","key":"2022063018185683600_CIT0011","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1530\/ERC-16-0206","article-title":"E2F1-mediated human POMC expression in ectopic Cushing\u2019s syndrome","volume":"23","author":"Araki","year":"2016","journal-title":"Endocr Relat Cancer."},{"issue":"5","key":"2022063018185683600_CIT0012","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0092-8674(94)90522-3","article-title":"Phosphorylation of E2F-1 modulates its interaction with the retinoblastoma gene product and the adenoviral E4 19 kDa protein","volume":"78","author":"Fagan","year":"1994","journal-title":"Cell."},{"issue":"3","key":"2022063018185683600_CIT0013","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/77124","article-title":"DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters","volume":"25","author":"Robertson","year":"2000","journal-title":"Nat Genet."},{"issue":"3","key":"2022063018185683600_CIT0014","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10561-008-9077-0","article-title":"Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies","volume":"9","author":"Ferrer","year":"2008","journal-title":"Cell Tissue Bank."},{"issue":"9","key":"2022063018185683600_CIT0015","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1158\/0008-5472.CAN-08-4617","article-title":"E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt\u2019s lymphoma","volume":"69","author":"Molina-Privado","year":"2009","journal-title":"Cancer Res."},{"issue":"5","key":"2022063018185683600_CIT0016","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/andr.12090","article-title":"E2F1 controls germ cell apoptosis during the first wave of spermatogenesis","volume":"3","author":"Rotgers","year":"2015","journal-title":"Andrology."},{"issue":"9","key":"2022063018185683600_CIT0017","doi-asserted-by":"crossref","first-page":"14777","DOI":"10.18632\/oncotarget.14833","article-title":"E2F-1 targets miR-519d to regulate the expression of the ras homolog gene family member C","volume":"8","author":"Sang","year":"2017","journal-title":"Oncotarget."},{"issue":"3","key":"2022063018185683600_CIT0018","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11102-005-1757-1","article-title":"Retrospective multicentric study of pituitary incidentalomas","volume":"7","author":"Day","year":"2004","journal-title":"Pituitary."},{"key":"2022063018185683600_CIT0019","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.3346\/jkms.2007.22.S.S61","article-title":"The characteristics of incidental pituitary microadenomas in 120 Korean forensic autopsy cases","volume":"22","author":"Kim","year":"2007","journal-title":"J Korean Med Sci"},{"issue":"1","key":"2022063018185683600_CIT0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1530\/eje.0.1440051","article-title":"ACTH silent adenoma shrinking under cabergoline","volume":"144","author":"Petrossians","year":"2001","journal-title":"Eur J Endocrinol."},{"issue":"10","key":"2022063018185683600_CIT0021","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1210\/jc.2010-0644","article-title":"Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience","volume":"95","author":"Raverot","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"2022063018185683600_CIT0022","first-page":"e3346","article-title":"Two distinctive POMC promoters modify gene expression in cushing disease","volume-title":"J Clin Endocrinol Metab.","author":"Araki","year":"2021"},{"issue":"3","key":"2022063018185683600_CIT0023","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1677\/joe.0.1770365","article-title":"Proopiomelanocortin gene expression and DNA methylation: implications for Cushing\u2019s syndrome and beyond","volume":"177","author":"Newell-Price","year":"2003","journal-title":"J Endocrinol."},{"issue":"2","key":"2022063018185683600_CIT0024","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1677\/jme.0.0150187","article-title":"Functional analysis of the human pro-opiomelanocortin promoter in the small cell lung carcinoma cell line DMS-79","volume":"15","author":"Picon","year":"1995","journal-title":"J Mol Endocrinol."},{"issue":"14","key":"2022063018185683600_CIT0025","first-page":"3276","article-title":"Glucocorticoid receptor structure and function in glucocorticoid-resistant small cell lung carcinoma cells","volume":"56","author":"Ray","year":"1996","journal-title":"Cancer Res."},{"issue":"1","key":"2022063018185683600_CIT0026","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1478-811X-8-32","article-title":"Phosphorylation meets nuclear import: a review","volume":"8","author":"Nardozzi","year":"2010","journal-title":"Cell Commun Signal."},{"issue":"1","key":"2022063018185683600_CIT0027","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12964-019-0456-x","article-title":"Karyopherin \u03b12-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer","volume":"17","author":"Drucker","year":"2019","journal-title":"Cell Commun Signal."},{"issue":"4","key":"2022063018185683600_CIT0028","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1128\/MCB.21.4.1384-1392.2001","article-title":"E2F4 is exported from the nucleus in a CRM1-dependent manner","volume":"21","author":"Gaubatz","year":"2001","journal-title":"Mol Cell Biol."}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqac086\/43989207\/bqac086.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqac086\/44358805\/bqac086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqac086\/44358805\/bqac086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T18:20:07Z","timestamp":1656613207000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqac086\/6604675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqac086","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,6,9]]},"article-number":"bqac086"}}